search innovation
Protein cages and methods for packaging and release of guest cargo objects
keywords: protein cage, cargo object, drug delivery, vaccination, particle, lumazine synthase, protein engineering, Aquifex aeolicus
offer number: 604

Hollow proteinaceous particles, referred to as protein cages, are useful for novel biotechnology development. Prospective applications using such nanocapsules include drug delivery, vaccination, catalysis, and in-cellulo production of otherwise unstable biomolecules. To achieve these goals, naturally occurring protein cages, e.g. virus-like particles, have been extensively engineered to endow them with customized functionality.

Lumazine synthase (LS), derived from several organisms such as Aquifex aeolicus, is known to form dodecahedral assemblies composed of 60 identical monomers. Due to extreme thermal stability, facile recombinant production, and high tolerance against both chemical and genetic modification, the enzyme derived from Aquifex aeolicus (AaLS) has been extensively employed for diverse applications including: biomineralization, drug delivery/vaccine, bioimaging, enzyme catalysis and as a robust guest encapsulation system. However, AaLS cages are very stable and require harsh conditions to induce their disassembly, hindering package and release of cargo molecules at arbitrary timing and location as required.

It has been shown that mutagenesis of AaLS changes the quaternary status of the protein. However, none of the previously engineered AaLS variants has shown cage conformation change in response to an external stimulus. Therefore, a challenge that has remained in the AaLS systems is to induce the cage opening and closing with a mild stimulus that is non-invasive to cargo molecules.

A new invention from the Jagiellonian University, which is the subject of this proposal, is a part of trend of searching for new solutions in protein engineering, especially in the AaLS systems. Its subject is protein cages, formed by novel engineered variants of lumazine synthase from Aquifex aeolicus (AaLS), that reversibly change the conformation in response to oxides, and also methods for packaging and release of guest cargo objects under mild physiological conditions.

 

The new invention of the Jagiellonian University provides:

  • new mutants of lumazine synthase from Aquifex aeolicus (AaLS). The AaLS variants contain mutations that moderately destabilize the cage-like assembly, which enables the oxide-dependent morphology changes. They assemble into cage-like structures that change the conformation from closed to open forms and vice versa in response to oxides;
  • a proteinaceous cage-like assembly comprising at least one AaLS variant of the invention;
  • an inclusion complex comprising protein cages of the invention and cargo molecules, wherein said cargo molecules are encapsulated in said protein cages;
  • methods for packaging and release of guest cargo objects under mild physiological conditions for:
  • changing the conformation of the protein cages formed by the AaLS variants of the inventions;
  • retrieving guest cargo from the protein cage of the invention;
  • packaging of guest cargo objects in the protein cages of the invention outside cellular contexts.

 

The offered invention is subject of a patent application. Further research and development of the invention are continued at the Malopolska Center of Biotechnology, Jagiellonian University Medical College. Currently, the Centre for Technology Transfer CITTRU is looking for entities interested in commercial application of the invention.

commercial utility:
Prospective applications using such nanocapsules include drug delivery, vaccination, catalysis, and in-cellulo production of otherwise unstable biomolecules.


field of science: biochemistry, bioengineering, biology, medical biology, medicine, microbiology, pharmaceutical science, health sciences, biotechnology
forms of protection: patent application
technological maturity: demanding R & D
property rights: Jagiellonian University
variants of cooperation: license, consulting, comercial contract research

information / broker of Jagiellonian University

name and surname: Klaudia Polakowska
phone number: 519329129
NEWS
latest information
ATOMIN 2.0 - ATOMic scale science for the INnovative economy

A center for atomic-scale materials research for an innovative economy, the so-called Atomin 2.0 project, has been established as a part of a joint venture of the Faculty of Chemistry and the Faculty of Physics, Astronomy and Applied Computer Science, Jagiellonian University.

Big Pharma Day online
Big Pharma Day online is an industry meeting on the development of drug projects, organized by CTT CITTRU, happening on March 25, 2021. The event will include expert presentations and individual meetings.
A new, effective method for obtaining common ash cuttings
Discover a new technology for obtaining cuttings of common ash developed by the interdisciplinary research team from the Jagiellonian University and the University of Agriculture in Krakow.
CITTRU team
Our employees
PARTNERS
Innovation Forum KrakówKlaster Lifescience KrakówWolves SummitPACTTJagiellońskie Centrum Innowacji
Contact
GET IN TOUCH WITH US
Centre for Technology Transfer CITTRU
Jagiellonian University in Kraków - POLAND
ul. Bobrzyńskiego 12,
30-348 Kraków

PHONE:
+48 12 664 42 00
E-MAIL:
cittru@uj.edu.pl
Fundusze EuropejskieMNiSWInkubator InnowacyjnościUnia Europejska